Iperion Limited Analysis

Overview

Iperion Limited (formally Southern Charter Financial Group Limited) is in the process of commercializing a novel antimicrobial coating product, being marketed under the name Pathoglaze. Early in 2023 Iperion entered into a license agreement granting the company an exclusive, worldwide, sub-licensable licence to manufacture, use, sell, distribute, import and export a self-cleaning, transparent, antimicrobial, surface coating product. A pilot manufacturing facility has since been established in Malaysia. The manufacturing facility and production is fully outsourced. The company is now actively marketing Pathoglaze.

Prior to 2023 the company did not have an operating business, but was searching for and investigating opportunities for acquiring a new business. This followed the completion of transactions on 31 August 2017 that injected cash, introduced a new controlling shareholder and spun-out all previous assets, liabilities and business operations.

Performance

The following information was extracted from Iperion Limited's half year results, released 28 November 2024:

Financial Results

Iperion reports an unaudited net loss attributable to shareholders of $363,730 for the half year ended 30 September 2024. This compares with a net loss attributable to shareholders of $462,614 for the same period last year.

There was no sales income in the period. The improvement in result compared to the same period last year is mainly related to the establishment of the outsourced pilot manufacturing plant that increased costs by $100,000 in the previous year.

Compared to the prior period, administrative expenses incurred in the half year ended September 2024 decreased by $14,715.